KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Debt to Equity (2016 - 2026)

Boston Scientific's Debt to Equity history spans 18 years, with the latest figure at $0.42 for Q1 2026.

  • On a quarterly basis, Debt to Equity fell 16.14% to $0.42 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.42, a 16.14% decrease, with the full-year FY2025 number at $0.47, down 4.4% from a year prior.
  • Debt to Equity hit $0.42 in Q1 2026 for Boston Scientific, down from $0.47 in the prior quarter.
  • Over the last five years, Debt to Equity for BSX hit a ceiling of $66.48 in Q2 2024 and a floor of -$312.32 in Q1 2024.
  • Historically, Debt to Equity has averaged -$18.51 across 5 years, with a median of $0.47 in 2023.
  • Biggest five-year swings in Debt to Equity: tumbled 195.83% in 2022 and later soared 1753.11% in 2024.
  • Tracing BSX's Debt to Equity over 5 years: stood at -$11.91 in 2022, then surged by 103.91% to $0.47 in 2023, then grew by 5.91% to $0.49 in 2024, then dropped by 4.4% to $0.47 in 2025, then fell by 10.47% to $0.42 in 2026.
  • Business Quant data shows Debt to Equity for BSX at $0.42 in Q1 2026, $0.47 in Q4 2025, and $0.49 in Q3 2025.